“…I know how my active PsA symptoms felt before and I know how much of my life I missed out on because of that. And, honestly, I can tell you that my worst day now is my best day then.“
- Suzana, real TREMFYA® patient
For US Healthcare Professionals
I am a
Rheumatology Specialist
For US Healthcare Professionals
Full Prescribing Information
Take confidence in TREMFYA®, the only* IL-23i proven to significantly inhibit structural damage progression† in a phase 3b study for adults with active PsA2,3
Provides Durable
Improvement Across Domains
TREMFYA® provides the opportunity for durable improvement across joint and multiple key domains of active PsA and 90% patient retention at 2 years.4-7‡§II¶
Open-label active treatment NRI post hoc analysis at Week 100.
No conclusions regarding efficacy or safety can be drawn from retention data.
Open-label active treatment NRI post hoc analysis at Week 100.
No conclusions regarding efficacy or safety can be drawn from retention data.
Safety Profile in
Psoriatic Disease#
TREMFYA® has a proven safety profile across psoriatic disease with 5 years of data in moderate to severe plaque psoriasis (PsO) and 2 years of data in
active PsA.1,4
A Differentiated
Mechanism
Selective IL-23 inhibitors like TREMFYA® block IL-23 and regulate IL-17A/F and IL-22 cytokines.**
TREMFYA® is the only†† selective, dual-acting‡‡ IL-23i designed also to
neutralize inflammation at its cellular source by binding to CD64.8**§§
**The clinical significance is unknown.
††Based on approved IL-23 inhibitors for active PsA as of August 2025.
‡‡Dual-acting is defined as blocking IL-23 and binding to CD64.
§§Findings are limited to in vitro studies.
Access options for all patients, and dedicated patient support
ACR20=20% improvement in American College of Rheumatology composite measures of arthritis; CD64=cluster of differentiation 64; IL=interleukin; IL-23i=interleukin-23 inhibitor; MOA=mechanism of action; mvdH-S=modified van der Heijde-Sharp; NRI=nonresponder imputation; PsA=psoriatic arthritis.
*Based on approved IL-23 inhibitors for active PsA as of June 2025.
†Major secondary endpoint in a phase 3b study.
‡The primary endpoint, ACR20 at Week 24, was met in the TREMFYA® arms in 2 clinical trials.
§Year 2 represents Week 100 in DISCOVER 2.
IIThrough Week 24, patients in DISCOVER 1 and
DISCOVER 2 were considered to be nonresponders after meeting treatment failure criteria (see study designs).
After
Week 24, treatment failure rules were not applied.
¶After Week 24, patients and doctors knew that all patients were on TREMFYA® (open label with a blinded dosing interval), which may have affected the results.
#Psoriatic disease is defined as moderate to severe plaque PsO and active PsA.
Access options for all patients, regardless of insurance coverage
92%* nationally preferred† first-line commercial coverage
No step edit required‡
ONCE A PRESCRIBING DECISION HAS BEEN MADE
*These percentages may not represent 100% of formulary lives due to data limitations.
†“Preferred” means TREMFYA® can be accessed first-line (ie, step therapy is not required) and its formulary status is better than or equivalent to other products in the class.
‡Requiring no step edits indicates a drug will be given first-line biologic access and will not require stepping through other biologic therapies.
References: 1. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Mease PJ, Ritchlin CT, Coates LC, et al. Inhibition of structural damage progression with guselkumab, a selective IL-23i, in participants with active PsA: Results through Week 24 of the phase 3b, randomized, double-blind, placebo-controlled APEX study. Oral presentation at: European Alliance of Associations for Rheumatology (EULAR) 2025 Congress; June 11-14, 2025; Barcelona, Spain. 3. Mease PJ, Ritchlin CT, Coates LC, et al. Inhibition of structural damage progression with guselkumab, a selective IL-23i, in participants with active PsA: Results through Week 24 of the phase 3b, randomized, double-blind, placebo-controlled APEX study. Abstract presented at: European Alliance of Associations for Rheumatology (EULAR) 2025 Congress; June 11-14, 2025; Barcelona, Spain. Late-Breaking Abstracts Session II. 4. Data on file. Janssen Biotech, Inc. 5. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomized, placebo-controlled phase 3 trial. Lancet. 2020;395(10230): 1126-1136. 6. McInnes IB, Rahman P, Gottlieb AB, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naïve patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74(3):475-485. 7. McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naïve patients with psoriatic arthritis. Arthritis Rheumatol.
2021;73(4):604-616. 8. Krueger J, Eyerich K, Greving C, et al. Differentiation of therapeutic antibodies targeting IL-23. Poster presented at: 2022 Society for Investigative Dermatology; May 18-21, 2022; Portland, OR.
